The FDA Desk — 2026-04-28

TITLE: FDA Desk — Apr 28: Sterility failures drive sweeping saline and vancomycin recalls; Teva pulls clonidine patches

---

Summary

No Class I actions posted today. Ten Class II drug recalls were published, dominated by a multi-lot Fresenius Kabi sodium chloride injection withdrawal for sterility assurance failures, paired Fagron vancomycin compounded-product recalls citing both sterility and a device-component defect, and a Teva/Actavis clonidine transdermal recall tied to CGMP violations.

Class II — Sterile Injectables

Fresenius Kabi — Sodium Chloride Injection, USP (multi-lot, freeflex bags)

Fresenius Kabi USA initiated a firm-led recall on 2026-03-11 of six saline injection presentations distributed in freeflex bags, all cited for Lack of Assurance of Sterility. The action spans concentrations and fill volumes used widely as IV vehicles and diluents:

• D-0424-2026 — 0.45% Sodium Chloride Injection, 1.125 g/250 mL (4.5 mg/mL), 250 mL freeflex bag (NDC 63323-626-03).
• D-0426-2026 — 0.9% Sodium Chloride Injection, 100 mL freeflex bag (NDC 65219-468-05).
• D-0427-2026 — 0.9% Sodium Chloride Injection, 250 mL freeflex bag (NDC 65219-470-05).
• D-0428-2026 — 0.9% Sodium Chloride Injection, 500 mL freeflex bag (NDC 65219-472-05).
• D-0432-2026 — 0.9% Sodium Chloride Injection, 500 mL Single Dose freeflex bag (NDC 65219-432-20).
• D-0430-2026 — 0.9% Sodium Chloride Injection, 100 mL Single Dose freeflex bag, manufactured by Fresenius Kabi and distributed by BD (Becton, Dickinson and Company), broadening downstream exposure beyond Fresenius's own label.

Clinically, the breadth of fill sizes and the BD co-distribution raise the likelihood that affected lots have entered hospital pharmacy par stock and admixture workflows; pharmacies should quarantine identified NDCs and reconcile against compounding records.

Fagron Sterile Services — Compounded Vancomycin in 0.9% Sodium Chloride

Fagron Compounding Services initiated two firm-led recalls on 2026-03-20 of compounded vancomycin admixtures, citing lack of assurance of sterility *and* a device defect — the blue Break-Off-Part on the administration port may detach. The combination of microbiological and mechanical risk in a high-acuity antibiotic warrants immediate clinical substitution rather than continued bedside use.

• D-0440-2026 — Vancomycin HCl 1.25 g in 250 mL 0.9% NaCl (NDC 71266-5083-01).
• D-0441-2026 — Vancomycin HCl 1.5 g in 250 mL 0.9% NaCl (NDC 71266-5085-01).

Class II — Transdermal Drug Products

Teva Pharmaceuticals USA initiated a firm-led recall on 2026-03-19 of two strengths of Clonidine Transdermal System, USP (manufactured by Actavis Laboratories UT, distributed by Actavis Pharma) for CGMP deviations involving use of an unapproved raw material. Patients on these patches for hypertension face potential blood-pressure destabilization on abrupt discontinuation; prescribers should plan oral bridge therapy where substitution is required.

• D-0472-2026 — Clonidine Transdermal System 0.1 mg/day, cartons of 4 systems with 4 adhesive covers.
• D-0473-2026 — Clonidine Transdermal System 0.2 mg/day, cartons of 4 systems with 4 adhesive covers.

Editor's Note

Today's docket is concentrated rather than diverse: a single sterility-assurance event at Fresenius Kabi accounts for six of ten entries and reaches the market through at least two distributors (Fresenius Kabi and BD). Health-system pharmacy buyers should treat this as a de facto saline supply event and verify that downstream relabelers have cascaded the recall.